ClinicalTrials.gg
CompletedNCT04782271Updated Mar 31, 2022

Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops

A Phase 1 interventional study of SYL18001 sodium Low dose q.d and SYL18001 sodium Middle dose q.d in Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers and Choroidal Neovascularization, sponsored by Sylentis, S.A.. Completed at 1 site in Spain. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by Sylentis, S.A. (part of PharmaMar) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Choroidal Neovascularization with a site in Spain — 2 open to participants now, 3 under way, 3 of them phase 3. Choroidal Neovascularization · Spain.

Enrollment
17th of 18
36 · median 279
Started
2021
the only one that year
Phase 1
Only one
of the 18
Registered
14th of 18
by date
Lead sponsor
1 of 18
Sylentis, S.A.

Among the 18 studies in Choroidal Neovascularization with a site in Spain, this one is the 17th largest by enrollment, is the only one that started in 2021, is the only one in phase 1, and was the 14th registered.

Choroidal Neovascularization

214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.

Browse Choroidal Neovascularization studies →

Open to participants now

2 of the 18 studies in Choroidal Neovascularization with a site in Spain are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Choroidal Neovascularization with a site in Spain, or all of them as a file.
02

Study summary

Study of the safety, tolerability and pharmacokinetic profile of different doses of SYL1801 eye drops in healthy volunteers.

03

Conditions studied

  • Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers
  • Choroidal Neovascularization

Keywords

  • Oligonucleotide
  • siRNA (Small Interfering Ribonucleic Acid)
  • Eye Drops
  • wet AMD (Age-related Macular Degeneration)
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • (BMI) between 19.5 and 29.0 kg/m2
  • Intraocular pressure (IOP) \<=21 mmHg
  • Best Corrected Visual Acuity (BCVA) >= 70 ETDRS
  • Normal corneal and conjunctival assessment
  • Normal funduscopy

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding females or those with a positive pregnancy test. Females of who will not use a medically acceptable method
  • Current relevant diseases according to the investigator's judgement.
  • Previous relevant chronic processes according to the investigator's judgement
  • Relevant visual alterations according to the investigator's judgement
  • Administration of systemic medications
  • Case history of to medicinal products or any other allergic process
  • Participation in any clinical study with an drug/device within 3 months prior to the first day of dosing.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Single administration Low Dose once daily

    1 treatment day

    Drug: SYL18001 sodium Low dose q.d

  • Experimental
    Single administration Middle Dose once daily

    1 treatment day

    Drug: SYL18001 sodium Middle dose q.d

  • Experimental
    Single administration High Dose once daily

    1 treatment day

    Drug: SYL18001 sodium High dose q.d

  • Experimental
    Single administration High Dose twice daily

    1 treatment day

    Drug: SYL18001 sodium High dose b.i.d

  • Experimental
    Multiple administrations Low Dose once daily

    7 treatment days

    Drug: SYL18001 sodium Low dose q.d

  • Experimental
    Multiple administrations Middle Dose once daily

    7 treatment days

    Drug: SYL18001 sodium Middle dose q.d

  • Experimental
    Multiple administrations High Dose once daily

    7 treatment days

    Drug: SYL18001 sodium High dose q.d

  • Experimental
    Multiple administrations High Dose twice daily

    7 treatment days

    Drug: SYL18001 sodium High dose b.i.d

Interventions

  • DrugSYL18001 sodium Low dose q.d

    1 drop in the randomized eye once daily

  • DrugSYL18001 sodium Middle dose q.d

    1 drop in the randomized eye once daily

  • DrugSYL18001 sodium High dose q.d

    1 drop in the randomized eye once daily

  • DrugSYL18001 sodium High dose b.i.d

    1 drop in the randomized eye twice daily

06

What researchers measure

Primary outcomes

  1. Ocular tolerability at the site of administration (cornea and conjunctiva) after last instillation of the assigned dose level (1 day of treatment).

    Slit lamp evaluation

    Time frame: 72 hours after last instillation

  2. Ocular tolerability at the site of administration (cornea and conjunctiva) after last instillation of the assigned dose level (7 days of treatment).

    Slit lamp evaluation

    Time frame: 72 hours after last instillation

  3. Determination of the maximum Plasma Concentration [Cmax]

    Time frame: - 15 - 30 minutes, 1- 4 and 24 hours after last administration

  4. Determination of the Area Under the Curve of plasma concentrations until the last extraction time [AUT 0-t]

    Time frame: - 15 - 30 minutes, 1- 4 and 24 hours after last administration

07

Study locations

1 site
  • Sylentis Clinical Trial Site
    Madrid, 28034, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Dec 2021, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2021
First posted
Mar 4, 2021
StartActual
Mar 17, 2021
Primary completionActual
Dec 21, 2021
CompletionActual
Dec 21, 2021
Last update
Mar 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04782271
Lead sponsor
Sylentis, S.A.
Responsible party
Sponsor
First posted
Mar 4, 2021
Start date
Mar 17, 2021
Primary completion
Dec 21, 2021
Completion
Dec 21, 2021
Last update
Mar 31, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion